6RK73

6RK73 is a covalent irreversible and specific UCHL1 inhibitor with an IC 50 of 0.23 µM. 6RK73 shows almost no inhibition of UCHL3 (IC 50 =236 µM). 6RK73 specifically inhibit UCHL1 activity in breast cancer In Vitro 6RK73 (5 μM; 1-3 hours) treatment displays strong inhibition of the TGFβ-induced pSMAD2 and pSMAD3, and a decrease of TβRI and total SMAD protein levels in MDA-MB-436 cells. ? 6RK73(5 μM; 24-48 hours) results migration significantly slower than the DMSO control group in MDA-MB-436 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: MDA-MB-436 cells Concentration: 5 µM Incubation Time: 24, 48 hours Result: Migrated significantly slower than the DMSO control group Western Blot AnalysisCell Line: MDA-MB-436 cells Concentration: 5 µM Incubation Time: 1, 2, 3 hours Result: Displayed strong inhibition of the TGFβ-induced pSMAD2 and pSMAD3, and a decrease of TβRI and total SMAD protein levels. In Vivo 6RK73 displays a potent inhibition of breast cancer extravasation in zebrafish . MCE has not independently confirmed the accuracy of these methods. They are for reference only. IC50& Target:IC50: 0.23 µM (UCHL1), 236 µM (UCHL3)

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet